Market Research Logo

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2015

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2015’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Peripheral T-Cell Lymphomas (PTCL) Overview
Therapeutics Development
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies
Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development
AB Science SA
Affimed Therapeutics AG
Bayer AG
Celgene Corporation
CerRx, Inc.
Chipscreen Biosciences Ltd
Eisai Co., Ltd.
Incyte Corporation
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Mundipharma International Ltd
Onxeo SA
Pfizer Inc.
Sanofi
Solasia Pharma K.K.
Spectrum Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AFM-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alemtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-055 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darinaparsin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denileukin diftitox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fenretinide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
forodesine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romidepsin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SH-7129 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tipifarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology
Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma
Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco
Nov 13, 2014: Onxeo Confirms Receipt of the $25M Milestone Payment on Beleodaq
Nov 06, 2014: Celgene To Present Phase II Trial Data On Romidepsin at American Society of Hematology Annual Meeting
Sep 16, 2014: Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq (belinostat) for Injection with Patent Term Adjustment till 2027
Aug 28, 2014: Onxeo Strengthens Beleodaq Patent Protection in the U.S. Until 2027
Jul 07, 2014: FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq (belinostat) for Injection
Jul 03, 2014: BioAlliance Pharma Receives FDA approval for Beleodaq
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2015
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Sanofi, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2015
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2015
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL) – Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report